James, N.D., et al. (2016) Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. The Lancet, 387, 1163-1177.
https://doi.org/10.1016/S0140-6736(15)01037-5

has been cited by the following article:

• TITLE: Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer

  AUTHORS: Sanjay Hinduja, Adnan Khan, Uzair B. Chaudhary

  KEYWORDS: Metastatic Prostate Cancer, Hormone Sensitive Disease

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.13, December 13, 2017

  ABSTRACT: Androgen deprivation therapy has been the mainstay of treatment for management of metastatic hormone sensitive prostate cancer. Recently conducted randomized controlled trials with docetaxel based chemotherapy have shed light on benefit of early use chemotherapy for hormone sensitive prostate cancer. In this review, we aim to comprehensively describe recent trials which are changing the paradigm in support of up front use of docetaxel based chemotherapy for metastatic hormone sensitive prostate cancer.